zalcitabine has been researched along with Thymus Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Irons, RD; Le, AT; Som, DB; Stillman, WS | 1 |
| Collins, BJ; Dunnick, JK; Elwell, MR; Heath, JE; Irwin, RD; Lindamood, C; Prejean, D; Rao, GN; Sanders, VM | 1 |
| Buckley, LA; Collins, BJ; Foley, JF; Giles, HD; Heath, JE; May, RD; Rao, GN | 1 |
3 other study(ies) available for zalcitabine and Thymus Neoplasms
| Article | Year |
|---|---|
2'3'-Dideoxycytidine-induced thymic lymphoma correlates with species-specific suppression of a subpopulation of primitive hematopoietic progenitor cells in mouse but not rat or human bone marrow.
Topics: Adult; Animals; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cells; Humans; Interleukin-3; Lymphoma, T-Cell; Male; Mice; Mice, Inbred C57BL; Rats; Recombinant Proteins; Species Specificity; Stem Cell Factor; Thymus Neoplasms; Zalcitabine | 1995 |
Induction of thymic lymphoma in mice administered the dideoxynucleoside ddC.
Topics: Animals; Antiviral Agents; Atrophy; Body Weight; Female; Intubation, Gastrointestinal; Lymphoma; Male; Mice; Mice, Inbred Strains; Organ Size; Thymus Gland; Thymus Neoplasms; Zalcitabine | 1995 |
Carcinogenicity of 2',3'-dideoxycytidine in mice.
Topics: Anemia; Animals; Anti-HIV Agents; Atrophy; Body Weight; Carcinogenicity Tests; CD4-CD8 Ratio; Female; Lymphoma, T-Cell; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Sex Factors; Species Specificity; Thymus Gland; Thymus Neoplasms; Time Factors; Tumor Suppressor Protein p53; Zalcitabine | 1996 |